News

ProMIS Neurosciences’ candidate PMN310 can specifically target toxic clusters of soluble amyloid-beta protein, and be safely administered at high doses with reduced risk of characteristic Alzheimer’s brain changes or swelling, according to clinical data. PMN310 has the potential for greater therapeutic potency compared with other amyloid-beta-directed antibodies…

Selected through the Alzheimer’s Drug Discovery Foundation’s (ADDF) Diagnostics Accelerator program, four scientists will share nearly $3.5 million to develop new biomarkers for early detection of Alzheimer’s disease and related dementia. Philanthropists, including ADDF co-founder Leonard Lauder, Bill Gates and Jeff and MacKenzie Bezos,…

Virtual reality may help improve the quality of life for people with dementia, including those with Alzheimer’s disease, by stimulating them to recall past memories, reduce aggressive behavior, and connect with caregivers, a study suggests. The study, “Bring the Outside In: Providing Accessible Experiences Through VR for People…

ProMIS Neurosciences researchers have discovered new antibody candidates that selectively bind to the neurotoxic form of the tau protein — one of the hallmarks of Alzheimer’s disease. These new antibodies join the company’s PMN310, a humanized antibody that attacks only toxic forms of the amyloid beta protein…

Scientists have found a series of brain alterations associated with Alzheimer’s disease that occur decades before the onset of the first symptoms. Identifying these biological and anatomical brain alterations in people at high-risk for the disease may help them receive earlier therapeutic interventions, the researchers said. The study, “…

The Alzheimer’s Drug Discovery Foundation (ADDF) has awarded $1.5 million to Oryzon Genomics to support expanding an ongoing Phase 2a trial assessing the potential of vafidemstat (ORY-2001) in patients with mild to moderate Alzheimer’s disease to the United States. The double-blind, placebo-controlled trial (2017-004893-32), called…

Alzheimer’s oral therapy candidate PRI-002, being developed by Priavoid, has proven safe for human use in healthy volunteers during a Phase 1 clinical trial. These positive trial results provide important evidence that supports progressing…

The U.S. Food and Drug Administration has approved Neuronascent’s investigational new drug (IND) application for NNI-362, its therapy candidate for Alzheimer’s disease, allowing it to move ahead with a Phase 1a clinical trial, the company announced. The first-in-human trial will evaluate the safety of NNI-362 in…

Elenbecestat and BAN2401, two potential anti-amyloid therapies, were selected by the Alzheimer’s Clinical Trials Consortium (ACTC) to be evaluated in clinical studies aiming to prevent progression to early stages of Alzheimer’s disease.

High blood levels of primary fatty acid amides (PFAMS), a class of fatty molecules involved in sleep and movement control, are associated with increased accumulation of beta-amyloid protein in the cerebrospinal fluid of patients with Alzheimer’s disease, a study finds. Researchers believe that this class of fatty…